BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets —Provides funding for BCX9930/oral Factor D program across multiple indications— —Agreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity— NEW YORK,...

Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates Phase 3 open-label extension completed on schedule in patients with negative symptoms of schizophrenia and data will be available in H1 2021 Minerva’s royalty interest in seltorexant acquired by...

Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million WALTHAM, Mass. and NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma will acquire...